Atrium Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
RNA$8.23-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $3,004 | $3,847 | $22,639 | $5,420 |
| Operating expenses: | ||||
| Research and development | 15,343 | 13,293 | 32,000 | 20,230 |
| General and administrative | 10,279 | 3,418 | 30,537 | 5,506 |
| Total operating expenses | 25,622 | 16,711 | 62,537 | 25,736 |
| Loss from operations | (22,618) | (12,864) | (39,898) | (20,316) |
| Other income (expense) | ||||
| Interest income | 2,104 | — | 2,757 | — |
| Other income (expense), net | 328 | (15) | 322 | (12) |
| Total other income (expense) | 2,432 | (15) | 3,079 | (12) |
| Net loss | $(20,186) | $(12,879) | $(36,819) | $(20,328) |
| Basic and diluted net loss per common share | $(1.18) | $(0.75) | $(2.15) | $(1.19) |
| Weighted average common shares outstanding used in the calculation of basic and diluted net loss per common share | 17,106 | 17,106 | 17,106 | 17,106 |
| Other comprehensive loss: | ||||
| Net unrealized loss on short-term investments | (235) | — | (235) | — |
| Comprehensive loss | $(20,421) | $(12,879) | $(37,054) | $(20,328) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.